FGFR4 and rhabdomyosarcoma: FGFR4 has been reported to be over-expressed in human breast, prostate, colon, rhabdomyosarcoma, gastric, pancreatic, hepatocellular and pituitary adenocarcinomas [4], [9], [10], [11], [12], [13], [14], [15], where it can contribute to tumor progression by multiple mechanisms [4], [9].